Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCS002c
- Development stage
- Preclinical
- Lead developer
- Glen Clova Scientific
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Injection
01
Overview
GCS002c is a virus-like particle (VLP)-based protein vaccine being developed by Glen Clova Scientific for the treatment of canine atopic dermatitis. The vaccine is designed to induce the production of neutralizing antibodies against interleukin-13 (IL-13), a key Th2 cytokine that plays a central role in the pathogenesis of allergic skin diseases in dogs. By stimulating the animal's own immune system to target IL-13, GCS002c aims to provide a long-acting therapeutic alternative to monoclonal antibodies, potentially offering improved convenience and cost-effectiveness for the management of chronic atopic dermatitis in veterinary patients.
02
Targets
IL-13 (Interleukin-13)
Beyond the preview
Go deeper on GCS002c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GCS002c.